In Brief: Lanax warning letter
This article was originally published in The Tan Sheet
Executive Summary
Lanax warning letter: Carma Labs receives notice from FDA that Lanax Ointment, a hemorrhoid treatment, fails to meet the requirements of the anorectal OTC monograph. Two ingredients, phenol and salicylic acid, are not considered safe and effective for treatment of hemorrhoids, FDA says. In addition, the product fails to bear appropriate warnings, directions and a statement of identity. Also, a January FDA inspection found "deviations" from the CGMP regs, including the failure of production and packaging records to show the amount of product packaged under the Lanex label...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: